Media Coverage · February 6, 2018
Acticor Biotech annonce la fin de son étude clinique de phase I avec son candidat ACT017 – Industrie Mag [FR]
February 2018. ACT017 est un fragment d’anticorps monoclonal humanisé (Fab) dirigé contre GPVI, une glycoprotéine plaquettaire impliquée dans les processus thrombotiques.
Download full text article (PDF, French)
Read next in 'Media Coverage'
- Novel antiplatelet could circumvent bleeding risk for stroke patients
- Experimental antiplatelet compound for acute stroke shows promise
- New drug to prevent clots clears safety hurdle
- New blood thinner may prevent stroke, without risk for bleeding
- Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke